Climara vs. Bijuve

See how Climara and Bijuve compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Climara is a once-weekly estrogen-only patch, while Bijuve is a once-daily capsule combining estradiol with progesterone in a single dose.

  • Both carry the same boxed warnings for blood clots, stroke, heart attack, dementia risk, and endometrial or breast cancer risk.

  • Climara covers a broader range of menopause-related uses, while Bijuve is approved only for hot flashes in women who still have a uterus.

Climara vs. Bijuve Drug Summary

Climara

Climara is a steroidal estrogen patch used for hormone replacement therapy. It treats hot flashes, vaginal atrophy, and hypoestrogenism from menopause or ovarian failure, and helps prevent postmenopausal osteoporosis. It is applied to the skin once a week in one of six doses.

Bijuve

Bijuve is a combination hormone capsule containing bioidentical estradiol and progesterone. It treats moderate to severe hot flashes caused by menopause in women who still have a uterus. It comes in two strengths and is taken by mouth once a day.

Climara vs. Bijuve Side Effects

Climara

Most common
headache (≥10%)
breast pain (≥10%)
abdominal pain (≥10%)
edema (≥10%)

Bijuve

Most common
breast tenderness (10.4%)
headache (3.4%)
vaginal bleeding (3.4%)
vaginal discharge (3.4%)

Climara vs. Bijuve Dosage

Climara

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.025 mg/day patch At the start
Maximum dose 0.1 mg/day patch If needed
Dose changes 5 increases As tolerated

Bijuve

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.5 mg/100 mg At the start
Maximum dose 1 mg/100 mg If needed
Dose changes 1 increase As tolerated

Climara vs. Bijuve Indications

Climara

Climara is FDA-approved for hot flashes, vaginal and vulvar atrophy, and low estrogen levels from menopause, ovarian failure, hypogonadism, or castration. It is also approved to help prevent bone loss after menopause. Some clinicians prescribe it off-label as part of feminizing hormone therapy for transgender women.

  • Moderate to severe hot flashes from menopause

  • Vulvar and vaginal atrophy from menopause

  • Hypoestrogenism from hypogonadism, castration, or ovarian failure

  • Prevention of postmenopausal osteoporosis

  • Off-label: feminizing hormone therapy for transgender women

Bijuve

Bijuve is FDA-approved only for moderate to severe hot flashes caused by menopause, and only in women who still have a uterus. It pairs bioidentical estradiol with bioidentical progesterone in one capsule, so a separate progestin pill is not needed. It is not approved for women without a uterus or for preventing heart disease, stroke, or dementia.

  • Moderate to severe hot flashes from menopause

  • Only approved for women with an intact uterus

  • Combines estradiol and progesterone in one capsule

  • Not approved for osteoporosis prevention

  • Not approved for women without a uterus

Climara vs. Bijuve Pros and Cons

Climara

Climara's transdermal delivery skips first-pass liver metabolism, which may lower clot risk compared with oral estrogens. It offers six patch strengths for fine-tuned dosing and covers a wider range of approved uses than Bijuve. Because it contains only estrogen, women with a uterus need to add a separate progestogen to protect against endometrial cancer.

Pros

  • Once-weekly patch instead of a daily pill

  • Transdermal route may carry lower clot risk than oral estrogen

  • Six dose strengths allow more precise titration

Cons

  • Estrogen-only formula requires an added progestogen for uterus protection

  • Patch can loosen with sweating, bathing, or exercise

  • Requires remembering to rotate and change the patch weekly

Bijuve

Bijuve combines bioidentical estradiol and progesterone into one daily capsule, so women with a uterus do not need a second progestin prescription. It is approved for hot flashes only and is not indicated for osteoporosis prevention or for women without a uterus. Because it is swallowed, it passes through the liver first, which can raise clotting risk compared with a patch.

Pros

  • Single capsule provides both estrogen and progesterone

  • No need for a separate progestin prescription in women with a uterus

  • Only FDA-approved bioidentical estradiol-progesterone combination capsule

Cons

  • Oral dosing passes through the liver first, which may raise clot risk

  • Approved only for hot flashes, a narrower use than Climara

  • Not approved for women without a uterus

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.